France preventive inhaler market is anticipated to grow at a substantial rate of 3.3% during the forecast period. As per French government agency, Business France, the country ranked as 4th globally and second in Europe for the medical device and technology industry. There are about 1,300 to 1,350 companies in French device manufacturer that generated a revenue of around $32 billion in 2017. The country is generating about $9.5 billion in 2017 by the export of medical devices. The medical device market is employing around 85,000 people in the country. This provides a significant base for the growth of a preventive inhaler market over the forecast period.
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/france-preventive-inhaler-market
France preventive inhaler market is segmented on the basis of device type, application, and end-user. On the basis of the device, the market is sub-segmented into the metered dosed inhaler and dry powdered inhaler. The dry powder inhaler is estimated to have the largest market share in the France preventive inhaler market due to providing an easy inhalation solution. Whereas, the market for metered dose inhaler is estimated to be the fastest-growing at a CAGR during the forecast period owing to innovations and collaborations by the companies for the development of metered dosed inhaler. Moreover, on the basis of application, the market has been classified into asthma and COPD diseases. In addition, based on the end-user, homecare and hospitals and clinics have been analyzed.
Browse for Full Report Description@ https://www.omrglobal.com/industry-reports/france-preventive-inhaler-market
Furthermore, the market is characterized by the presence of several manufacturers that are developing and providing preventive inhalers to cater to a wide range of customers within the region and across the globe. The major players of the France preventive inhaler market include Boehringer Ingelheim International GmbH, AstraZeneca PLC, GlaxoSmithKline PLC, Novartis AG, Teva Pharmaceuticals Industries Ltd., Koninklijke Philips N.V., and Air Liquide S.A. These players adopt various strategies to capitalize on market growth opportunities. Mergers and acquisitions, product launch, geographical expansion, partnerships, and collaborations are the majorly adopted strategies by the market players.
A major inhaler manufacturing company in France is Air Liquide. In April 2018, the company acquired a French start-up company EOVE for the extension of service offering of home healthcare activities. In September 2017 Air Liquide acquired Sogo Sangyo Kabushiki Kaisha for expanding its healthcare business in Japan. In September 2017 company has launched its first e-health solution Chronic care Connect which is a remote monitoring solution. In January 2017 Air Liquide acquired Oxymaster for expanding its healthcare business in South America.
Market Segmentation
France Preventive Inhaler Market by Device Type
- Metered Dose Inhaler
- Dry Powder Inhaler
France Preventive Inhaler Market by Application
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
France Preventive Inhaler Market by End-User
- Homecare
- Hospitals and Clinics
Company Profiles
- 3M Co.
- Acorda Therapeutics, Inc.
- Adamis Pharmaceuticals Corp.
- Adherium Ltd.
- Air Liquide S.A.
- AstraZeneca PLC
- Bespak
- Boehringer Ingelheim International GmbH
- Chiesi Farmaceutici S.P.A.
- GlaxoSmithKline PLC
- H&T Presspart Manufacturing Ltd.
- Koninklijke Philips N.V.
- Novartis AG
- Omron Healthcare Inc.
- ResMed Corp.
- Pulmatrix Inc.
- Savara, Inc.
- Teicos Pharma Ltd.
- Teva Pharmaceuticals Industries Ltd.
- Vitalograph Ltd.
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
